KRAS and neoplasm: In addition, even though KL NSCLCs have lower PD-L1 expression when compared with the other KRAS mutated patients, the presence of mutations resulted independent on tumor mutational burden score and the association of LKB1 mutations with worse outcome was also confirmed among PD-L1 positive subgroup of KL NSCLC treated with ICIs.